The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
Open accessAbstract
Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved function of polycomb repressive complex 2 (PRC2) that mediates coordinated transcriptional silencing of the MHC-I antigen processing pathway (MHC-I APP), promoting evasion of T cell-mediated immunity. MHC-I APP gene promoters in MHC-I low cancers harbor bivalent activating H3K4me3 and repressive H3K27me3 histone modifications, silencing basal MHC-I expression and restricting cytokine-induced upregulation. Bivalent chromatin at MHC-I APP genes is a normal developmental process active in embryonic stem cells and maintained during neural progenitor differentiation. This physiological MHC-I silencing highlights a conserved mechanism by which cancers arising from these primitive tissues exploit PRC2 activity to enable immune evasion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Cancer Cell 36, 1–17, O This is an open access article und recognize and kill cells displaying foreign antigens bound to MHC class I (MHC-I) molecules (Gubin et al., 2014; Tumeh et al., 2014).”
BackgroundIntegrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368 · cited 1×
“, 2018), and NT2-D1 from GEO: GSE31755 (ENCOD (D and E) Chromatin state discovery tracks in selected human embryonic stem ChromHMM software integrating H3K27me3, H3K4me3, H3K27ac, and H3K36 (Kundaje et al., 2015).”
BackgroundA bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340
Self-citationChiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“Cancer Cell 36, 1–17, O This is an open access article und recognize and kill cells displaying foreign antigens bound to MHC class I (MHC-I) molecules (Gubin et al., 2014; Tumeh et al., 2014).”
BackgroundRoulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease
Durbin, J. E., Hackenmiller, R., Simon, M. C., & Levy, D. E. (1996) · Cell · doi:10.1016/s0092-8674(00)81289-1 · Cited by 1,242
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Role of the polycomb protein EED in the propagation of repressive histone marks
Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury III, W. J., Voigt, P., Martin, S. R., Taylor, W. R., De Marco, V., et al. (2009) · Nature · doi:10.1038/nature08398 · Cited by 1,196
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C., & Yusa, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2800 · Cited by 1,064
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946
Self-citationOser, M. G., Niederst, M. J., Sequist, L. V., & Engelman, J. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71180-5 · Cited by 942
Identification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852
A double take on bivalent promoters
Voigt, P., Tee, W.-W., & Reinberg, D. (2013) · Genes & Development · doi:10.1101/gad.219626.113 · Cited by 815
Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Sheng, W., LaFleur, M. W., Nguyen, T. H., Chen, S., Chakravarthy, A., Conway, J. R., Li, Y., Chen, H., Yang, H., Hsu, P.-H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.052 · Cited by 693
Meuwissen, R., Linn, S. C., Linnoila, R. I., Zevenhoven, J., Mooi, W. J., & Berns, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00220-4 · Cited by 643
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 632
Identification of human cancers deficient in antigen processing.
Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mulé, J. J., Rosenberg, S. A., & Bennink, J. R. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.2.265 · Cited by 624
Sutherland, K. D., Proost, N., Brouns, I., Adriaensen, D., Song, J.-Y., & Berns, A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.019 · Cited by 534
Self-citationChemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Gardner, E. E., Lok, B. H., Schneeberger, V. E., Desmeules, P., Miles, L. A., Arnold, P. K., Ni, A., Khodos, I., de Stanchina, E., Nguyen, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.006 · Cited by 526
Unravelling the biology of SCLC: implications for therapy
Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.71 · Cited by 490
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer
Comet, I., Riising, E. M., Leblanc, B., & Helin, K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.83 · Cited by 432
Aubrey, B. J., Kelly, G. L., Kueh, A. J., Brennan, M. S., O’Connor, L., Milla, L., Wilcox, S., Tai, L., Strasser, A., & Herold, M. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.002 · Cited by 399
NLRC5: a key regulator of MHC class I-dependent immune responses
Kobayashi, K. S., & van den Elsen, P. J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3339 · Cited by 384
Tumor immune evasion arises through loss of TNF sensitivity
Kearney, C. J., Vervoort, S. J., Hogg, S. J., Ramsbottom, K. M., Freeman, A. J., Lalaoui, N., Pijpers, L., Michie, J., Brown, K. K., Knight, D. A., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aar3451 · Cited by 381
Self-citationGenome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens
Morgens, D. W., Wainberg, M., Boyle, E. A., Ursu, O., Araya, C. L., Tsui, C. K., Haney, M. S., Hess, G. T., Han, K., Jeng, E. E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15178 · Cited by 360
Harutyunyan, A. S., Krug, B., Chen, H., Papillon-Cavanagh, S., Zeinieh, M., De Jay, N., Deshmukh, S., Chen, C. C. L., Belle, J., Mikael, L. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09140-x · Cited by 360
A probability-based approach for the analysis of large-scale RNAi screens
König, R., Chiang, C.-Y., Tu, B. P., Yan, S. F., DeJesus, P. D., Romero, A., Bergauer, T., Orth, A., Krueger, U., Zhou, Y., et al. (2007) · Nature Methods · doi:10.1038/nmeth1089 · Cited by 338
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Zingg, D., Arenas-Ramirez, N., Sahin, D., Rosalia, R. A., Antunes, A. T., Haeusel, J., Sommer, L., & Boyman, O. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.007 · Cited by 330
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
Wang, D., Quiros, J., Mahuron, K., Pai, C.-C., Ranzani, V., Young, A., Silveria, S., Harwin, T., Abnousian, A., Pagani, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.050 · Cited by 318
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
Qi, W., Zhao, K., Gu, J., Huang, Y., Wang, Y., Zhang, H., Zhang, M., Zhang, J., Yu, Z., Li, L., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2304 · Cited by 316
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., Campisi, M., Kuang, Y., Zhang, Y., Gjini, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0116-5 · Cited by 312
N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma
Bernards, R., Dessain, S. K., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90509-x · Cited by 301
Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis
Wang, L., Jin, Q., Lee, J.-E., Su, I.-H., & Ge, K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000031107 · Cited by 295
Polycomb-like proteins link the PRC2 complex to CpG islands
Li, H., Liefke, R., Jiang, J., Kurland, J. V., Tian, W., Deng, P., Zhang, W., He, Q., Patel, D. J., Bulyk, M. L., et al. (2017) · Nature · doi:10.1038/nature23881 · Cited by 289
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Paulson, K. G., Voillet, V., McAfee, M. S., Hunter, D. S., Wagener, F. D., Perdicchio, M., Valente, W. J., Koelle, S. J., Church, C. D., Vandeven, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06300-3 · Cited by 286
The Tasmanian Devil Transcriptome Reveals Schwann Cell Origins of a Clonally Transmissible Cancer
Murchison, E. P., Tovar, C., Hsu, A., Bender, H. S., Kheradpour, P., Rebbeck, C. A., Obendorf, D., Conlan, C., Bahlo, M., Blizzard, C. A., et al. (2010) · Science · doi:10.1126/science.1180616 · Cited by 248
Siddle, H. V., Kreiss, A., Tovar, C., Yuen, C. K., Cheng, Y., Belov, K., Swift, K., Pearse, A.-M., Hamede, R., Jones, M. E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219920110 · Cited by 245
Self-citationModulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy
Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., Xiong, L., Trojer, P., Aparicio, A., Subudhi, S. K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99760 · Cited by 244
Quiescent tissue stem cells evade immune surveillance
Agudo, J., Park, E. S., Rose, S. A., Alibo, E., Sweeney, R., Dhainaut, M., Kobayashi, K. S., Sachidanandam, R., Baccarini, A., Merad, M., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.02.001 · Cited by 244
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer
Jiang, L., Huang, J., Higgs, B. W., Hu, Z., Xiao, Z., Yao, X., Conley, S., Zhong, H., Liu, Z., Brohawn, P., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005895 · Cited by 241
Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma
Zeid, R., Lawlor, M. A., Poon, E., Reyes, J. M., Fulciniti, M., Lopez, M. A., Scott, T. G., Nabet, B., Erb, M. A., Winter, G. E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0044-9 · Cited by 230
Mechanisms regulating PRC2 recruitment and enzymatic activity
Holoch, D., & Margueron, R. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.04.003 · Cited by 201
Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma
Stafford, J. M., Lee, C.-H., Voigt, P., Descostes, N., Saldaña-Meyer, R., Yu, J.-R., Leroy, G., Oksuz, O., Chapman, J. R., Suarez, F., et al. (2018) · Science Advances · doi:10.1126/sciadv.aau5935 · Cited by 191
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
Mehta, A., Kim, Y. J., Robert, L., Tsoi, J., Comin-Anduix, B., Berent-Maoz, B., Cochran, A. J., Economou, J. S., Tumeh, P. C., Puig-Saus, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1178 · Cited by 183
Sato, T., Kaneda, A., Tsuji, S., Isagawa, T., Yamamoto, S., Fujita, T., Yamanaka, R., Tanaka, Y., Nukiwa, T., Marquez, V. E., et al. (2013) · Scientific Reports · doi:10.1038/srep01911 · Cited by 178
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2
Chen, L., Alexe, G., Dharia, N. V., Ross, L. S., Iniguez, A. B., Conway, A. S., Wang, E. J., Veschi, V., Lam, N., Qi, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90793 · Cited by 157
Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2
Lee, C., Holder, M., Grau, D., Saldaña-Meyer, R., Yu, J.-R., Ganai, R. A., Zhang, J., Wang, M., LeRoy, G., Dobenecker, M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.03.019 · Cited by 153
Gene bivalency at Polycomb domains regulates cranial neural crest positional identity
Minoux, M., Holwerda, S. J. B., Vitobello, A., Kitazawa, T., Kohler, H., Stadler, M. B., & Rijli, F. M. (2017) · Science · doi:10.1126/science.aal2913 · Cited by 152
Tilburgs, T., & Strominger, J. L. (2013) · American Journal of Reproductive Immunology · doi:10.1111/aji.12094 · Cited by 128
MHC class II presentation of endogenously expressed antigens by transfected dendritic cells
Diebold, S. S., Cotten, M. L., Koch, N., & Zenke, M. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301433 · Cited by 121
Functional interdependence of BRD4 and DOT1L in MLL leukemia
Gilan, O., Lam, E. Y. N., Becher, I., Lugo, D., Cannizzaro, E., Joberty, G., Ward, A., Wiese, M., Fong, C. Y., Ftouni, S., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3249 · Cited by 119
Self-citationGenetic interplay between HLA-C and MIR148A in HIV control and Crohn disease
Kulkarni, S., Qi, Y., Ó’hUigín, C., Pereyra, F., Ramsuran, V., McLaren, P. J., Fellay, J., Nelson, G. W., Chen, H., Liao, W. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312237110 · Cited by 104
Wee, Z. N., Li, Z., Lee, P. L., Lee, S. T., Lim, Y. P., & Yu, Q. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.045 · Cited by 101
Regulation of T Cell Differentiation and Function by EZH2
Karantanos, T., Chistofides, A., Barhdan, K., Li, L., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00172 · Cited by 81
The Multiple Facets of PRC2 Alterations in Cancers
Wassef, M. A., & Margueron, R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.012 · Cited by 72
Veer, L. J. V., Beijersbergen, R. L., & Bernards, R. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05645.x · Cited by 71
Polycomb Repressive Complex 2 Methylates Elongin A to Regulate Transcription
Ardehali, M. B., Anselmo, A. N., Cochrane, J. C., Kundu, S., Sadreyev, R. I., & Kingston, R. E. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.10.025 · Cited by 63
EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms
Ueda, T., Sanada, M., Matsui, H., Yamasaki, N., Honda, Z.-I., Shih, L.-Y., Mori, H., Inaba, T., Ogawa, S., & Honda, H. (2012) · Leukemia · doi:10.1038/leu.2012.146 · Cited by 54
Locus-Specific Analysis of Human Leukocyte Antigen Class I Expression in Melanoma Cell Lines
Marincola, F. M., Shamamian, P. E., Simonis, T. B., Abati, A. D., Hackett, J., Dea, T. O., Fetsch, P. A., Yannelli, J. R., Restifo, N. P., Mulé, J. J., et al. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199407000-00002 · Cited by 52
Sequence and Phylogenetic Analysis of the Untranslated Promoter Regions for HLA Class I Genes
Ramsuran, V., Hernández‐Sánchez, P. G., Ó’hUigín, C., Sharma, G., Spence, N., Augusto, D. G., Gao, X., García-Sepúlveda, C. A., Kaur, G., Mehra, N. K., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601679 · Cited by 41
Flies, A. S., Lyons, A. B., Corcoran, L. M., Papenfuss, A. T., Murphy, J. M., Knowles, G. W., Woods, G. M., & Hayball, J. D. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00581 · Cited by 40
Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways
Hassan, M. A. E., Huang, K., Eswara, M. B. K., Zhao, M., Lan, S., Tao, Y., Liu, Y., Liu, J., McCurdy, S. R., Ma, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126466 · Cited by 38
Expression of classical HLA class I molecules: regulation and clinical impacts
René, C., Lozano, C., & Eliaou, J. (2016) · HLA · doi:10.1111/tan.12787 · Cited by 35
Cited by
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01233-9 · Cited by 826
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Metadata
- Authors
- Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., Jackson, S., Tan, L., Wong, S. Q., Hollizeck, S., Michalak, E. M., Siddle, H. V., McCabe, M. T., Prinjha, R. K., Guerra, G. R., Solomon, B. J., Sandhu, S., Dawson, S.-J., Beavis, P. A., Tothill, R. W., Cullinane, C., Lehner, P. J., Sutherland, K. D., & Dawson, M. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 36
- Issue
- 4
- Pages
- 385-401.e8
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2970548174
- Cited by
- 649
- References
- 77
- FWCI
- 18.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.